Zhejiang CONBA Pharmaceutical Co Ltd
Zhejiang CONBA Pharmaceutical Co.,Ltd. engages in the research, development, production, and sales of pharmaceuticals and health products in mainland China. It offers medicines, Chinese patent medicines, chemical medicines, Chinese herbal medicine slices, and health products. The company also provides Chinese decoction pieces; over-the-counter medications; healthy consumer products, including nut… Read more
Zhejiang CONBA Pharmaceutical Co Ltd (600572) - Total Liabilities
Latest total liabilities as of September 2025: CN¥2.97 Billion CNY
Based on the latest financial reports, Zhejiang CONBA Pharmaceutical Co Ltd (600572) has total liabilities worth CN¥2.97 Billion CNY as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Zhejiang CONBA Pharmaceutical Co Ltd - Total Liabilities Trend (2001–2024)
This chart illustrates how Zhejiang CONBA Pharmaceutical Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Zhejiang CONBA Pharmaceutical Co Ltd Competitors by Total Liabilities
The table below lists competitors of Zhejiang CONBA Pharmaceutical Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Zotye Automobile Co Ltd
SHE:000980
|
China | CN¥3.35 Billion |
|
Asker Healthcare Group AB
F:I88
|
Germany | €8.78 Billion |
|
IperionX Limited American Depositary Share
NASDAQ:IPX
|
USA | $12.59 Million |
|
Bank First National Corp
NASDAQ:BFC
|
USA | $3.88 Billion |
|
HomeCo Daily Needs REIT
PINK:HDNRF
|
USA | $1.89 Billion |
|
China TransInfo Technology Co Ltd
SHE:002373
|
China | CN¥6.00 Billion |
|
Teijin Limited
F:TIJ
|
Germany | €582.57 Billion |
|
Bossard Holding AG
OTCGREY:BHAGF
|
USA | $556.50 Million |
Liability Composition Analysis (2001–2024)
This chart breaks down Zhejiang CONBA Pharmaceutical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.83 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.42 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.29 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Zhejiang CONBA Pharmaceutical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Zhejiang CONBA Pharmaceutical Co Ltd (2001–2024)
The table below shows the annual total liabilities of Zhejiang CONBA Pharmaceutical Co Ltd from 2001 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥2.99 Billion | -23.13% |
| 2023-12-31 | CN¥3.89 Billion | +7.84% |
| 2022-12-31 | CN¥3.61 Billion | +6.04% |
| 2021-12-31 | CN¥3.40 Billion | -13.45% |
| 2020-12-31 | CN¥3.93 Billion | -20.10% |
| 2019-12-31 | CN¥4.92 Billion | -0.06% |
| 2018-12-31 | CN¥4.92 Billion | +37.59% |
| 2017-12-31 | CN¥3.58 Billion | -10.74% |
| 2016-12-31 | CN¥4.01 Billion | -19.92% |
| 2015-12-31 | CN¥5.00 Billion | +70.85% |
| 2014-12-31 | CN¥2.93 Billion | +57.26% |
| 2013-12-31 | CN¥1.86 Billion | -11.23% |
| 2012-12-31 | CN¥2.10 Billion | +55.60% |
| 2011-12-31 | CN¥1.35 Billion | +80.42% |
| 2010-12-31 | CN¥747.34 Million | -4.28% |
| 2009-12-31 | CN¥780.76 Million | +20.19% |
| 2008-12-31 | CN¥649.60 Million | -6.31% |
| 2007-12-31 | CN¥693.32 Million | +10.37% |
| 2006-12-31 | CN¥628.20 Million | +12.07% |
| 2005-12-31 | CN¥560.55 Million | +34.63% |
| 2004-12-31 | CN¥416.37 Million | +21.67% |
| 2003-12-31 | CN¥342.22 Million | +30.68% |
| 2002-12-31 | CN¥261.88 Million | -1.45% |
| 2001-12-31 | CN¥265.74 Million | -- |